Search clinical trials for: Interleukin 2

Total 16527 results

The First Hospital of Jilin University

Completed

The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura (HSP)

Purpura, Schoenlein-Henoch

China
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis

Vasculitis | Wegener's Granulomatosis

United States
Clinigen, Inc.
Johns Hopkins University; M.D. Anderson Cancer Center

Terminated

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma (PROCLIVITY02)

Metastatic Melanoma

United States
Peking University People's Hospital

Completed

Anti-infection of Low-does IL-2 in SLE

Systemic Lupus Erythematosus

China
Peking University People's Hospital
Monash University

Completed

Low-dose IL-2( Interleukin-2) Treatment in SLE

Systemic Lupus Erythematosus

China
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Prometheus Laboratories

Active, not recruiting

Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

Chronic Graft-versus-host Disease

United States
Peking University People's Hospital

Terminated

Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation

Leukemia

China
Beni-Suef University

Completed

Serum Interleukin 6 in Chronic Obstructive Pulmonary Disease

Chronic Obstr Lung Disease

Egypt
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Cancer

Melanoma | Breast Cancer | Colorectal Cancer | Lung Cancer | Bone Cancer | Rectal Cancer | Uterine Sarcoma | Colon Cancer | Ovarian Sarcoma | Eye Cancer | Adult Soft Tissue Sarcoma

United States
Beijing YouAn Hospital

Unknown

Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC

Hepatocellular Carcinoma

China
Yi Miao
Nanjing Abingen Biotech Co. Ltd

Unknown

T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System

Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Bowel Cancer | Liver Cancer | Gallbladder Cancer

China
Sohag University

Not yet recruiting

THE VALUE OF INTERLEUKIN 6 AS A DIAGNOSTIC MARKER IN NEONATAL SEPSIS

NEONATAL SEPSIS

Egypt
Sandoz

Completed

A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia

HIV Infections | Cytopenias

United States
National Cancer Institute (NCI)

Terminated

Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer

Kidney Neoplasms

United States
University of Minnesota
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) (SILCAAT)

HIV Infection

United States
Peking University People's Hospital

Unknown

Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation

Acute Graft-versus-host Disease

China
NYU Langone Health
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma | Regional Neuroblastoma

United States
Centre Hospitalier St Anne
For Drug Consulting

Recruiting

Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD (IL-2-AD)

Alzheimer Disease

France
Sohag University
Sohag General Hospital

Not yet recruiting

Evaluation of Serum Levels of Interlukin-15 and Interlukin-21 in Patients With Alopecia Areata

Alopecia Areata

Egypt
Oxford BioMedica
Columbia University; ORION Clinical Services

Completed

A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer

Carcinoma, Renal Cell

United States
Dana-Farber Cancer Institute
Novartis; Brigham and Women's Hospital

Completed

Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease

Graft Versus Host Disease

United States
Novo Nordisk A/S

Completed

Efficacy Study of IL-21 to Treat Metastatic Melanoma

Cancer | Malignant Melanoma

Australia
National University Hospital, Singapore

Completed

A Pilot Study of Autologous Ex Vivo Activated NK Cell Infusion in the Treatment of Metastatic Nasopharyngeal Carcinoma

Metastatic Nasopharyngeal

Singapore
BGI, China
Wuhan Union Hospital, China

Recruiting

HPV-T in HPV-16 Positive Recurrent or Metastatic Solid Tumors (GI-HPVT-01)

Solid Tumor

China
Peking University People's Hospital

Recruiting

Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial

Systemic Lupus Erythematosus

China
University of Wisconsin, Madison
National Cancer Institute (NCI); EMD Serono

Completed

Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

Melanoma

United States
Cytheris SA

Terminated

Study on Interleukin-7 (CYT107) in HIV Patients (Inspire 2)

HIV

United States, Canada
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Interleukin-7 in Treating Patients With Refractory Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma

Stage IV Melanoma

United States
Hoffmann-La Roche

Completed

A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Belgium, France, Germany, Sweden, Switzerland, Turkey, Greece, Taiwan, Estonia, Slovakia, Italy, Romania, Lithuania, Serbia, Portugal, Egypt, Pakistan, Mexico, Peru, Lebanon, United States, Argentina, Chile, Kuwait, Latvia, Macedonia, The... and more
Centre Leon Berard
Ministry of Health, France; Cytheris, Inc.

Completed

Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients

Metastatic Breast Cancer

France
Massachusetts General Hospital

Terminated

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

Melanoma

United States
Celularity Incorporated

Terminated

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Iovance Biotherapeutics, Inc.

Active, not recruiting

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC

Completed

The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial (ACTIVATE)

Advanced Ovarian Cancer | Malignant Melanoma

Canada
National Institute of Allergy and Infectious Diseases...

Completed

Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 Studies

HIV Infections

United States
Inge Marie Svane

Completed

T-cell Based Immunotherapy for of Melanoma

Melanoma

Denmark
Inge Marie Svane

Withdrawn

T-cell Based Immunotherapy for Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma

Denmark
Oslo University Hospital
University of Oslo; Lovisenberg Diakonale Hospital

Withdrawn

Effects of Intraarticular IL1-Ra on Pain and Inflammatory Mediators After Knee Arhroscopy

Knee Injuries

Norway
United States Naval Medical Center, San Diego
CEL-SCI Corporation

Terminated

Safety Study of Multikine in the Treatment of Perianal Warts

Condyloma

United States
Wake Forest University Health Sciences
Emory University

Completed

A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas (Poly-ICLC)

Brain Tumors

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Prometheus Laboratories; Miltenyi Biomedicine...

Active, not recruiting

Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

Chronic Graft Versus Host Disease | Chronic GVHD | Complications of Organ Transplant Stem Cells

United States
Assiut University

Unknown

Expression of Inflammasomes in HCV Patients (Inflammasome)

Hepatitis C
CINJRegulatory
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
University of Wisconsin, Madison

Completed

Eosinophilic Airway Inflammation and Mepolizumab

Asthma

United States
ZymoGenetics

Completed

Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer

Melanoma | Kidney Neoplasms | Metastases

United States
National Cancer Institute (NCI)

Completed

Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis

Psoriasis

United States
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)

Completed

FT516 and IL2 With Enoblituzumab for Ovarian Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer | Fallopian Tube Adenocarcinoma

United States

Search clinical trials for: Interleukin 2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations